Guanfacine treatment for prefrontal cognitive dysfunction in older participants: a randomized clinical trial.
Guanfacine treatment for prefrontal cognitive dysfunction in older participants: a randomized clinical trial.
复制标题
鸟明治疗老年参与者的前额叶认知功能障碍:一项随机临床试验。
DOI:
10.1016/j.neurobiolaging.2018.05.033
复制
发表时间:
2018-10
影响因子:
4.2
通讯作者:
van Dyck CH
中科院分区:
文献类型:
--
作者:
Barcelos NM;Van Ness PH;Wagner AF;MacAvoy MG;Mecca AP;Anderson GM;Trentalange M;Hawkins KA;Sano M;Arnsten AFT;van Dyck CH
This study evaluated the effect of the alpha-2A-adrenoceptor agonist guanfacine on prefrontally-mediated cognitive functions, as well as quality of life and global function in healthy older participants. One hundred twenty-three participants 75-years and older were randomly assigned to guanfacine 0.5 mg, 0.1 mg, or placebo daily for 12 weeks. The primary outcome measure was the change in z-score for 6 prefrontal executive function tasks over 12 weeks (PEF6). Neither dose of guanfacine improved PEF6 z-score relative to placebo. The rate of mean change [95% confidence interval] in PEF6 z-score over 12 weeks was 0.270 [0.159, 0.380] for placebo, compared with 0.121 [0.011, 0.232] for guanfacine 0.1 mg (p = 0.06, compared to placebo), and 0.213 [0.101, 0.324] for 0.5 mg (p = 0.47). Neither dose of guanfacine improved quality of life or global function relative to placebo. Among common adverse events, only dry mouth was significantly more frequent on guanfacine compared to placebo. Guanfacine failed to ameliorate prefrontal cognitive function in older individuals, who were cognitively normal for age.
登录
查看更多内容
影响因子:
34.7
作者:
Morrison, John H.;Baxter, Mark G.
通讯作者:
Baxter, Mark G.
影响因子:
3.4
作者:
Franowicz, JS;Arnsten, AFT
通讯作者:
Arnsten, AFT
DOI:
10.1076/jcen.24.2.221.993
发表时间:
2002-01-01
影响因子:
2.2
作者:
Daigneault, G;Joly, P;Frigon, JY
通讯作者:
Frigon, JY
影响因子:
7.6
作者:
Jäkälä, P;Riekkinen, M;Riekkinen, P
通讯作者:
Riekkinen, P
影响因子:
7.6
作者:
Jäkälä, P;Sirviö, J;Riekkinen, P
通讯作者:
Riekkinen, P